Based on the ION-2 data, GILD’s GT1 regimen will include ribavirin for treatment-experienced patients, which means the regimen will effectively be BID, not qD. For treatment-naïve patients (possibly excluding cirrhotics), GILD will have a bona fide qD regimen.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.